Capstone Investment Advisors
CSTL icon

Capstone Investment Advisors’s Castle Biosciences CSTL Stock Holding History

Capstone Investment Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,677
Closed -$380K – 1684
2025
Q3 		$380K Buy
+16,677
New +$339K ﹤0.01% 1542

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Capstone Investment Advisors's CSTL Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Castle Biosciences (CSTL) in Q4 2025, closing a stake of 16,677 shares — an estimated $380K sold.

Capstone Investment Advisors first reported a position in CSTL in Q3 2025 and held it in 1 quarter. The position peaked at $380K in Q3 2025. 194 funds tracked by Wall St. Rank hold CSTL as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Castle Biosciences position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 16,677 Castle Biosciences shares in Q4 2025, an estimated $380K.
  • Capstone Investment Advisors first reported a position in Castle Biosciences in Q3 2025 and held it in 1 quarter.
  • Capstone Investment Advisors's Castle Biosciences position peaked at $380K in Q3 2025.
  • 194 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.